Type your tag names separated by a space and hit enter

Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease.

Abstract

INTRODUCTION

Mitochondrial complex I deficiencies have been found in post-mortem brains of patients with Parkinson's disease (PD). Coenzyme Q10 (CoQ10) is the electron acceptor found in complexes I and II, and is a potent antioxidant. A recent trial of the oxidized form of CoQ10 for PD failed to show benefits; however, the reduced form of CoQ10 (ubiquinol-10) has shown better neuroprotective effects in animal models.

METHODS

Randomized, double-blind, placebo-controlled, parallel-group pilot trials were conducted to assess the efficacy of ubiquinol-10 in Japanese patients with PD. Participants were divided into two groups: PD experiencing wearing off (Group A), and early PD, without levodopa (with or without a dopamine agonist) (Group B). Participants took 300 mg of ubiquinol-10 or placebo per day for 48 weeks (Group A) or 96 weeks (Group B).

RESULTS

In Group A, total Unified Parkinson's Disease Rating Scale (UPDRS) scores decreased in the ubiquinol-10 group (n = 14; mean ± SD [-4.2 ± 8.2]), indicating improvement in symptoms. There was a statistically significant difference (p < 0.05) compared with the placebo group (n = 12; 2.9 ± 8.9). In Group B, UPDRS increased in the ubiquinol-10 group (n = 14; 3.9 ± 8.0), as well as in the placebo group (n = 8; 5.1 ± 10.3).

CONCLUSIONS

This is the first report showing that ubiquinol-10 may significantly improve PD with wearing off, as judged by total UPDRS scores, and that ubiquinol-10 is safe and well tolerated.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Neurology, Juntendo University School of Medicine, Japan; Department of Neurology, Juntendo University Koshigaya Hospital, Japan.

    ,

    Department of Neurology, Juntendo University School of Medicine, Japan.

    ,

    School of Bioscience and Biotechnology, Tokyo University of Technology, Japan.

    ,

    Department of Neurology, Juntendo University School of Medicine, Japan.

    ,

    Department of Neurology, Juntendo University School of Medicine, Japan.

    ,

    School of Bioscience and Biotechnology, Tokyo University of Technology, Japan.

    ,

    School of Bioscience and Biotechnology, Tokyo University of Technology, Japan.

    ,

    Department of Neurology, Higashi Nagoya National Hospital, Japan.

    Department of Neurology, Juntendo University School of Medicine, Japan. Electronic address: nhattori@juntendo.ac.jp.

    Source

    Parkinsonism & related disorders 21:8 2015 Aug pg 911-6

    MeSH

    Aged
    Antioxidants
    Double-Blind Method
    Female
    Humans
    Male
    Middle Aged
    Neuroprotective Agents
    Parkinson Disease
    Pilot Projects
    Treatment Outcome
    Ubiquinone

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    26054881

    Citation

    Yoritaka, Asako, et al. "Randomized, Double-blind, Placebo-controlled Pilot Trial of Reduced Coenzyme Q10 for Parkinson's Disease." Parkinsonism & Related Disorders, vol. 21, no. 8, 2015, pp. 911-6.
    Yoritaka A, Kawajiri S, Yamamoto Y, et al. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. Parkinsonism Relat Disord. 2015;21(8):911-6.
    Yoritaka, A., Kawajiri, S., Yamamoto, Y., Nakahara, T., Ando, M., Hashimoto, K., ... Hattori, N. (2015). Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. Parkinsonism & Related Disorders, 21(8), pp. 911-6. doi:10.1016/j.parkreldis.2015.05.022.
    Yoritaka A, et al. Randomized, Double-blind, Placebo-controlled Pilot Trial of Reduced Coenzyme Q10 for Parkinson's Disease. Parkinsonism Relat Disord. 2015;21(8):911-6. PubMed PMID: 26054881.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. AU - Yoritaka,Asako, AU - Kawajiri,Sumihiro, AU - Yamamoto,Yorihiro, AU - Nakahara,Toshiki, AU - Ando,Maya, AU - Hashimoto,Kazuhiko, AU - Nagase,Midori, AU - Saito,Yufuko, AU - Hattori,Nobutaka, Y1 - 2015/05/29/ PY - 2015/01/04/received PY - 2015/05/25/revised PY - 2015/05/27/accepted PY - 2015/6/10/entrez PY - 2015/6/10/pubmed PY - 2016/5/7/medline KW - Complex I KW - Oxidative stress KW - Parkinson's disease KW - Randomized controlled trial KW - Reduced form of coenzyme Q10 SP - 911 EP - 6 JF - Parkinsonism & related disorders JO - Parkinsonism Relat. Disord. VL - 21 IS - 8 N2 - INTRODUCTION: Mitochondrial complex I deficiencies have been found in post-mortem brains of patients with Parkinson's disease (PD). Coenzyme Q10 (CoQ10) is the electron acceptor found in complexes I and II, and is a potent antioxidant. A recent trial of the oxidized form of CoQ10 for PD failed to show benefits; however, the reduced form of CoQ10 (ubiquinol-10) has shown better neuroprotective effects in animal models. METHODS: Randomized, double-blind, placebo-controlled, parallel-group pilot trials were conducted to assess the efficacy of ubiquinol-10 in Japanese patients with PD. Participants were divided into two groups: PD experiencing wearing off (Group A), and early PD, without levodopa (with or without a dopamine agonist) (Group B). Participants took 300 mg of ubiquinol-10 or placebo per day for 48 weeks (Group A) or 96 weeks (Group B). RESULTS: In Group A, total Unified Parkinson's Disease Rating Scale (UPDRS) scores decreased in the ubiquinol-10 group (n = 14; mean ± SD [-4.2 ± 8.2]), indicating improvement in symptoms. There was a statistically significant difference (p < 0.05) compared with the placebo group (n = 12; 2.9 ± 8.9). In Group B, UPDRS increased in the ubiquinol-10 group (n = 14; 3.9 ± 8.0), as well as in the placebo group (n = 8; 5.1 ± 10.3). CONCLUSIONS: This is the first report showing that ubiquinol-10 may significantly improve PD with wearing off, as judged by total UPDRS scores, and that ubiquinol-10 is safe and well tolerated. SN - 1873-5126 UR - https://www.unboundmedicine.com/medline/citation/26054881/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S1353-8020(15)00240-0 DB - PRIME DP - Unbound Medicine ER -